Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 TIP (paclitaxel + ifosfamide + cisplatin/carboplatin) in metastatic non-transitional cell carcinoma of the bladder and urinary tract
2014-000043-32Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Jan 2014
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of paclitaxel, ifosfamide, cisplatin and carboplatin in bladder cancer and transitional cell carcinoma (TCC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Jan 2014; status: completed.
02
Drugs
paclitaxelifosfamidecisplatincarboplatin
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2014-000043-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000043-32.